The Real Story Behind CagriSema's 20% Weight Loss Results
A clinician's nine-minute response to headlines calling CagriSema a failure, covering the REDEFINE 4 comparison with tirzepatide and how the two drugs act in the brain.
With Dr. Dan
Key moments
Tap a moment to play the video from there.
- 0:00Was CagriSema really a flop?Dr. Dan says headlines calling CagriSema a failure miss the point of a 20% weight loss. He previews the REDEFINE 4 trial and the brain mechanisms of both drugs.
- 0:47REDEFINE 4 trial and resultsHe describes the non-inferiority design against tirzepatide 15 mg weekly. He reports 20.2% weight loss for CagriSema versus 23.6% for tirzepatide at 84 weeks, and that non-inferiority was not achieved.
- 2:47The 15% sweet spotDr. Dan argues that diminishing returns apply, and that about 15% weight loss captures most health benefits. He says lifestyle habits drive further gains.
- 4:01Precision obesity medicineHe says obesity has many phenotypes, such as stress eating, never feeling full, food noise or a sluggish metabolism. A drug that falls short on average may fit an individual well.
- 5:17How tirzepatide worksHe describes tirzepatide's GLP-1 and GIP components acting in the hypothalamus and reward center. He says GIP also improves insulin sensitivity in fat tissue.
- 6:37How CagriSema worksDr. Dan says the semaglutide part acts on the hypothalamus and reward center, while amylin acts in the area postrema as a satiation signal. He asks viewers which description fits them.
- 8:22Final verdictHe concludes that CagriSema technically missed the trial goal but still adds options for patients and clinicians. He credits Novo Nordisk for reporting the data.
What the video says
Dr. Dan, who describes himself as a clinician working in obesity medicine, responds to headlines saying CagriSema "crashed and burned" after the REDEFINE 4 trial. His argument is that a drug producing about 20% weight loss should not be framed as a flop, and that the coverage treats obesity medications like a winner-take-all race.
He explains the trial as a non-inferiority, head-to-head design. CagriSema, which he describes as semaglutide plus the amylin analog cagrilintide, was compared with tirzepatide at 15 mg once weekly. At 84 weeks, in the per protocol analysis, he reports weight loss of 20.2% from baseline for CagriSema and 23.6% for tirzepatide, so CagriSema did not achieve non-inferiority. He calls that a heavy blow for Novo Nordisk and its investors, but still a very strong result from a clinical point of view.
The middle of the video is about why he thinks the gap matters less than the headlines suggest. Dr. Dan says that around 15% weight loss delivers most of the health gains, such as lower blood pressure, less liver fat and steadier metabolic markers, and compares 20% versus 23% to 170 versus 190 mph when the limit is 70. He adds that further gains come from activity, diet and sleep. He also argues for precision obesity medicine: because people overeat for different reasons, he suggests one drug may suit a given person better than another. On why the two drugs differ in results, he says the cause is not entirely known.
The last section compares mechanisms using a raccoon and nightclub bouncer metaphor. Tirzepatide, a GLP-1 and GIP combination, is described as acting in the hypothalamus and the reward center, with GIP boosting GLP-1 effects and acting on fat tissue. CagriSema pairs the semaglutide component, which he places in those same areas, with amylin acting in the hindbrain area postrema as a meal-ending satiation signal. The video also includes a short pitch for his paid community hub and prompts for comments.
On each compound
CagriSema0:47
Dr. Dan reports that in REDEFINE 4 CagriSema produced 20.2% weight loss from baseline at 84 weeks versus 23.6% for tirzepatide, missing non-inferiority. He calls the result impressive for patients and says it adds options.
See how your DNA reads CagriSemaTirzepatide5:17
Dr. Dan describes tirzepatide as a GLP-1 and GIP combination acting in the hypothalamus and reward center. He says its GIP component also improves insulin sensitivity in fat tissue.
See how your DNA reads TirzepatideSemaglutide6:37
He describes semaglutide as the GLP-1 component of CagriSema, working in the hypothalamus and reward center to calm cravings.
See how your DNA reads SemaglutideCagrilintide6:37
Dr. Dan describes cagrilintide as a new amylin analog that acts in the hindbrain's area postrema. He says it governs satiation, the physical signal to end a meal.
See how your DNA reads Cagrilintide“amylin isn't a whisperer, amylin is the bouncer at the nightclub”
What this video doesn’t settle
- The video gives only two headline weight-loss figures and no safety, side-effect, dosing or tolerability data for either drug.
- Dr. Dan says the reason for the weight-loss gap between CagriSema and tirzepatide is not entirely known, and his mechanism explanation is offered as a likely account with metaphors.
- The claim that individual patients will respond better to one drug or the other is argued in general terms, with no data on who responds to which.
Questions this video answers
Did CagriSema fail in the REDEFINE 4 trial?
Dr. Dan says it technically did not achieve non-inferiority against tirzepatide, with 20.2% versus 23.6% weight loss at 84 weeks. He argues that calling a 20% result a flop is misleading.
How does CagriSema compare with tirzepatide for weight loss?
In the per protocol analysis he cites, CagriSema led to 20.2% weight loss from baseline and tirzepatide at 15 mg weekly led to 23.6%. He says the reason for the difference is not entirely known.
How much weight loss gives most of the health benefits?
Dr. Dan says about 15% of body weight captures the vast majority of the benefits, such as lower blood pressure, less liver fat and stabilized metabolic markers. He says gains beyond that are mostly extra.
How is amylin different from GLP-1 in CagriSema?
According to Dr. Dan, the semaglutide GLP-1 component works in the hypothalamus and reward center, while the amylin analog works in the hindbrain's area postrema. He describes amylin as the physical satiation signal that ends a meal.
Video by Dr. Dan | Obesity Expert on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
